Noninvasive diagnostic methods in primary lung cancer : part two: computerized axial tomography of the chest and positron emission tomography

Métodos diagnósticos no invasivos en cáncer pulmonar primario : segunda parte: tomografía axial computarizada de tórax y tomografía con emisión de positrones

Published 2008-09-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 20 No. 3 (2008)
Section
Métodos diagnósticos en neumología
How to Cite
Noninvasive diagnostic methods in primary lung cancer : part two: computerized axial tomography of the chest and positron emission tomography.
rev. colomb. neumol. [Internet]. 2008 Sep. 1 [cited 2024 Nov. 22];20(3):119-27.
DOI
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Alirio Bastidas
Médico Internista - Residente II año Neumología, Hospital Militar Central. Bogotá, Colombia.
    Plutarco Garcia Herreros
    Médico, Neumólogo Instituto Nacional de Cancerología – Universidad Nacional de Colombia. Bogotá, Colombia.
      Alfredo Saavedra
      Médico Internista – Neumólogo, Instituto Nacional de Cancerología – Universidad Nacional de Colombia. Bogotá, Colombia.
        Edgar Sánchez
        Médico Internista – Neumólogo, Instituto Nacional de Cancerología – Universidad Nacional de Colombia. Bogotá, Colombia.
          Show authors biography

          On the basis of currently available literature, this paper reviews primary lung cancer is a world wide public health problem which generates immense costs to the health system and where its cure is only achieve by an early diagnosis associated to an opportune surgical treatment. For this purpose several non invasive diagnostic methods are currently available, among them the sputum cytology, chest radiography, computed tomography scanner and the positron emission tomography. In the present article, constituted by two parts, the usefulness of these diagnostic methods as screening, diagnosis, staging and follow up tools will be discuss on the basis of the current available literaure for this type of neoplasm.

          Article visits 43 | PDF visits 132

          Downloads

          Download data is not yet available.
          1. Mancer RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer, Cochrane Database Syst Rev. 2004; (1): CD001991.
          2. Zoorob R, Anderson R, Cefalu C, Sinani M, Cancer Screening Gidelines, Am Fam Physician 2001; 63: 1101-1112.
          3. Collins L, Haines C, Perkel R, Enck R, Lung Cancer: Diagnosis and Management, Am Fam Physician 2007; 75: 56-63.
          4. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242-1245.
          5. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
          6. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771.
          7. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-265.
          8. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-961.
          9. National Lung Screening Trial- What is the appropriate measure of screening effectiveness? Available at: http:// www.cancer.gov/nlst/what-is-nlst#10b (accessed Abril 12, 2008).
          10. Greenwald P. A favorable view: progress in cancer prevention and screening. Recent Results Cancer Res 2007;174:3-17.
          11. MacRedmond R, Logan PM, Lee M, Kenny D, Foley C, Costello RW, Screening for lung cancer using low dose CT scanning, Thorax 2004; 59(3):237-241.
          12. Parthiv J, Mahadevia, Lung Cancer Screening With Helical Computed Tomography in Older Adult Smokers: A Decision and Cost-effectiveness Analysis, JAMA, 2003; 289 (3): 313.
          13. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, Pelosi G, Boyle P, Fazio F. Early lung-cancer detection with spiral CT and positron emission tomogrphy in heavy smokers: 2-year results. Lancet, 2003, 362: 593-597.
          14. Fraser R, Colman N, Mûller N, Paré PD, Pulmonary neoplams en: Synopsis of Diseases of the Chest. 1999. Chapter 7, p 337 - 422.
          15. Stewart J, MacMahon H, Viborny C, Pollak E, Dystrophic calcification in carcinoma of the pulmon: demonstration by CT. Am J Roentgenol 1987; 148:29.
          16. Mahoney M, Shipley R. Corcoran H, Dickson B. CT demonstration of calcification in carcinoma of the lung. Am J Roentgenol 1990; 154: 255.
          17. Nelson B, Wiot J, Some less familiar roentgen manifestations of carcinoma of the lung. Semin Roentgenol 1977; 12: 187.
          18. Lehar TJ, Carr DT, Millar WE, Payne WS, Woolner LB. Roentgenografphic appearance of bronchogenic adenocarcinoma. Am Rev Respir Dis 1967; 96: 245.
          19. Byrd RB, Millar WE, Carr DT, Payne WS, Woolner LB, The roentgenographic appearance of small cell carcinoma of the bronchus. Mayo Clin Proc 1968; 43:337.
          20. Byrd RB, Millar WE, Carr DT, Payne WS, Woolner LB, The roentgenographic appearance of large cell carcinoma of the bronchus. Mayo Clin Proc 1968; 43:333.
          21. Byrd RB, Millar WE, Carr DT, Payne WS, Woolner LB, The roentgenographic appearance of squamous cell carcinoma of the bronchus. Mayo clin Proc 1968; 43:327.
          22. Byrd RB, Millar WE, Carr DT, Payne WS, Woolner LB, Radiographic The roentgenographic appeaabnormalities in carcinoma of the lung as related to histological cell type. Thorax 1969; 24: 573.
          23. Erasmus J, Patz E, McAdams H, Evaluation of adrenal masses in patientes with bronchogenic carcinoma using 18F-fluorodeoxyglucose postitron emisión tomography. Am J Roentgenol 1997; 168: 1357.
          24. Siegelman S, Khouri N, Leo F, Fishman E, Baverman R, Zerhouni E. Solitary pulmonary nodules: CT assessment. Radiology 1986; 160: 307.
          25. Muhm J, McCullough A, The enhancing rim: a new signo f a benign pulmonary nodule. Mayo Clin Proc 2003; 78: 1092.
          26. Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology 1986;160:319–27.
          27. Takashima S, Sone S, Li F, et al. Small solitary pulmonary nodules (1 or ¼ 1 cm) detected at population-based CT screening for lung cancer: reliable high-resolution CT features of benign lesions. Am J Roentgenol 2003;180:955–64.
          28. Siegelman SS, Khouri NF, Leo FP, et al. Solitary pulmonary nodules: CT assessment. Radiology 1986; 160:307–12.
          29. Siegelman SS, Khouri NF, Scott J, et al. Pulmonary hamartoma: CT findings. Radiology 1986;160: 313–7.
          30. Woodring JH, Fried AM, Chuang VP. Solitary cavities of the lung wall: diagnostic implications of cavity wall thickness. Am J Roentgenol 1980; 135:1269–71.
          31. Woodring JH, Fried AM. Significance of wall thickness in solitary cavities of the lung: a follow-up study. Am J Roentgenol 1983;140:473–4.
          32. KuiM,TempletonPA,WhiteCS, et al. Evaluation of the air bronchogram sign on CT in solitary pulmonary lesions. J Comput Assist Tomogr 1996;20:983–6.
          33. Lee KS, Kim Y, Han J, et al. Bronchioloalveolar cell carcinoma: clinical, histopathologic, and radiologic findings. Radiographics 1997;17:1345–57.
          34. Winer-Muram HT. The solitary pulmonary nodule. Radiology 2006;239:34–49.
          35. Yankelevitz DF, Reeves AP, Kostis WJ, et al. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology 2000;217:251–6.
          36. Revel M-P, Merlin A, Peyrard S, et al. Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. Am J Roentgenol 2006;187: 135–42.
          37. Swensen S, Viggiano RW,Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214:73–80.
          38. Jeong YJ, Lee KS, Jeong SY, et al. Solitary pulmonary nodule: characterization with combined washin and washout features at dynamic multi-detector row CT. Radiology 2005;237:675–83.
          39. Chern MS, Wu MH, Cang CY. CT and MRI for staging or locally advanced non-small cell lun cancer. Lung Cancer, 2003: 42: S5-S8.
          40. Munden RF, et al. Imaging OF the patient with non-small cell lung cancer: what the clinican wants to know. Radiology. 2006; 803-818.
          41. Dunninck NR, Korobkin M, Francis IR. Adrenal radiology: distinguishsing bening from malignant masses. Am J Roentgenol. 1996. 167: 861-867.
          42. Dunnick NR, Korobkin M. Imaging of adrenal incidentalotas: current status. Am J Roentgenol. 2002; 179: 559-568.
          43. Silvestre GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer: a meta-analysis. Am R. Respir Crit Care Med. 1995; 152: 225-230.
          44. Walsh GL, et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Torac Surg. 1995; 606: 1563-1570.
          45. Pfister DG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: uptate 2003. J Clin Oncol. 2004; 22: 330-353
          46. Laroche C, Fairbaim I, Moss H, Pepke-Zaba J, Sharples L, Flower C, Coulden Richard. Role of Computed Tomographic Scanning of the thorax prior to bronchoscopy in the investigation of suspected lung cancer. Thorax 2000; 55: 359-363.
          47. Lancen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucosa levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993;34(3):355-9.
          48. Baldwin D, Birchall J, Ganatra R, Ponton K. Evaluation of the solitary pulmonary nodule: clinical management, role of CT and nuclear medicine. Imaging 2004;16:22.
          49. Carreras JL, Tomografía por emisión de positrones (PET) en neumología, Arch Bronconeumol 2002; 38: 345-347.
          50. Antoch G, Vogt F, Freudenberg L, Nazaradh F, Goehde S, Barkhausen J, Dahmen G, Bockisch A, Debatin J, Ruehm S, Whole-Body Dual-Modality PET/CT and Whole-Body MRI for Tumor Staging in Oncology. JAMA 2003; 290 (24): 3199-3206.
          51. Carreras JL, Tomografía por emisión de positrones (PET) en el nódulo solitario pulmonar. An R Acad Nac Med 2001; 118: 405-419.
          52. Richter JA, Torre W, Gámez C, Aramendia JM, Crespo A, Nicolas A, Valor de la tomografía por emisión de positrones (PET) – 18 FDG en el cáncer de pulmón. Med Clin 1999; 113: 567-571.
          53. Hagberg RC, Segall GM, Stara P, Burdon TA, Pompili MF. Characterization of pulmnary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose posiron emission tomography. Eur J Cardiothorac Surg 1997; 12: 92-97.
          54. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Tyschon K. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997; 112: 416-422.
          55. Patz EF Jr, Lowe VJ, Hoffman Jm, et al: Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-490.
          56. Gould MK, Maclean CC, Kuschener WG, et al: Accuracy of positron emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075-1084.
          57. Graeber G, Gupta N, Murray G, Positron Emission Tomographic imaging with Fluorodeoxyglucosa is Efficacious in Evaluating Malignant Pulmonary Disease, J Thorac Cardiovasc Surg 1999;117:719-727
          58. Erasmus J, McAdams, HP, Patz E, Goodman, PC, Coleman R. Thoracic FDG PET: state of the art. Radiographics 1998; 18:5.
          59. Nomori H, Watanabe K, Ohtsuka M, Evaluation of F-18 fluoro-deoxy-glucose (FDG) PET scaning for pulmonary nodules less than 3 cm in diameter, with special referente to the CT images. Lung Cancer 2004; 45:19.
          60. García C, Cabrera P, Freixinet J, Rodríguez P, Hussein M, Romero T, Textilota intratorácico interpretado como carcinoma broncogénico. Otro falso positive de la tomografía por emission de positrons, Arch Bronconeumol, 2007; 43(5): 292-294.
          61. Blue J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog 99mTc Depreotide in the evaluation of solitary pulmonary nodules. Chest 2000; 117: 1232.
          62. Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K, Taki S, Higuchi T, Tonami H, Yamamoto I. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET Eur J Nucl Med Mol Imag 2004; 31:13–21.
          63. Halter G, Buck AK, Schirrmeister H, Wurziger I, Liewald F, Glatting G, Neumaier B, Sunder-Plassmann L, Reske SN, Hetzel M. [18F] 3-deoxy-3 -fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg 2004; 127:1093–1099.
          64. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expresión with (18F) FDG uptake in non-small cell cancer. Eur U Nucl Med 2000; 27: 1778-1785.
          65. Gould MK, Lillington GA. Strategy and cost in investigating solitary pulmonary nodules. Thorax 1998; 53: S32-S7.
          66. Tinturen H, Hoekstra O, Smit E, Van den Bergh J, Schreurs JM, Stallaert R, Van Venthoven P, Comans E, Dlepenhorst F, Verboom P, Van Mourik J, Postmus P, Borres M, Teule G, Effectiveness of positronemission tomography in the preoperative assessment of patients with suspected non small-cell lung cancer: the PLUS mulicentre randomised trial. Lancet 2002; 359:1388-1392.
          67. Ginsberg MS, Grewal RK, Heelan Robert, Lung Cancer, Radiologic Clinics of North America, 2007, Vol 45 (1); 21-43.
          68. Hetzel M, Hetzel J, Arslandemir C, Nûssle K, Schirrmeister H, Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study. BMJ 2004;328: 1051-1052.
          69. Weder W, Schmid R, Bruchhaus, Hillinger Sven, Von Sxhulthess G, Steinert H, Detection of Extrathoracic metastases by Positron Emission Tomography in lung cancer. Ann Thorac Surg 1998;66:886-893.
          70. Gould M, Kushner W, Rydzak C, Maclean C, Demas A, Shigemitsu H, Chan J, Owens D, Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer. Ann Intern Med 2003;139:879-892.
          71. Lauer M, Murthy S, Blackstone E, Okereke I, Rice T. [18F] Fluorodeoxyglucose Uptake by Positron Emission Tomographyfor Diagnosis of Suspected Lung Cancer, Arch Intern Med 2007;167:161-165.
          72. J Watch 2000 Sep 1;20(17);135, commentary can be found in N Engl J Med 2000 Nov 23;343(21):1571.
          73. Reed CE, et al. Results of the American College of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003; 126: 1943-1951.
          74. Viney RC, et al. Randomized controlled trial of the role of positron emisión tomography in the management of stage I and II non small-cell lung cancer. J Clin Oncol. 2004; 22: 2357-2362.
          75. N Engl J Med 2000 Jul 27;343(4):254, editorial can be found in N Engl J Med 2000 Jul 27;343(4):290;
          76. Mah K, Caldwell CB, Ung YC, Danjuoux CE, Balogh JM, Ganguli SN, et al. The impact of 18-FDG-PET on target and critical organs in CT-bases treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002; 52: 339-350.
          77. Lardinois D, Weder W, Harry T, Karmel E, Korom S, Seifert B, Von Schulthess G, Steinert H, Staging of Non-Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed Tomography, N Engl J Med 2003;348:2500-2507.
          78. American College of Radiology (ACR) Appropriateness Criteria for staging of bronchogenic carcinoma, non-small cell and small cell lung carcinoma can be found in National Guideline Clearinghouse 2006 Mar 27:8309 in www.acr.org.
          79. Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989; 5: 119-124.
          80. Wischenberger JB, Cox CS Jr. Staging and surgery for lung cancer. J Thorac Imaging. 1991; 84: 641-648.
          81. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of samall cell lung cancer. Eur J Nucl Med 2001; 28: 483-488.
          82. Johnson BE. Second lung cancer in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90: 1335- 1345.
          83. Suzuki K, et al. Magnetic resonante imaging and computed tomography in the diagnosis of brain metastases of lung cancer. Lung Cancer. 2004. 46: 357-360.
          84. Ahuja V. Coleman RE, Rendón J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 1998; 83: 918-924.
          85. Donnie P. Dunagan, Robert Chin, Jr., Trent W. McCain, L. Doug Case, Beth A. Harkness, Timothy Oaks, and Edward F. Haponik Staging by Positron Emission Tomography Predicts Survival in Patients With Non-small Cell Lung Cancer Chest, Feb 2001; 119: 333 - 339.
          86. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 gluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival agter lung cancer resection. J Clin Oncol 2004; 22: 2355-2360.
          87. Sasaki R. Komaki R, Macapinlac H, et al. (18F) fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143.
          88. Higashi K, Ueda Y, Arisaka Y, et al. 18-F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43: 39-45.
          89. Patz EF Jr, et al. Connolly JE, Herndon Je II. Prognostic value of thoracic FDG PET imaging after tratment for non-small cell lung cancer. Am J Roentgenol. 2000; 174: 769-774.
          90. Pandit N, et al. Prognostic value of (F-18) FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003; 30: 78-84.
          91. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Cur Respir J. 1999; 14: 1376-1380.
          92. Duhaylongsod F, Lowe VJ, Patz J, Vaughn A, Coleman E, Wolfe W. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thor Cardiovasc Surg 1995; 110 (1): 130-140.
          93. Juweid ME, Cheson BD. Current concepts: positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354: 496-507
          94. Vansteenkiste J, et al. Positron emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004; 5: 531-540.
          95. Dimena B, Sonnad S, Angogaldo J, Wal R. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s – meta-analytic comparison of PET and CT. Radiology 1999; 213: 530.
          96. Pieterman R, Van Putten J, Meuezelaar J, Preoperative staging of non-small cell lung cancer with positron emission tomography. N Eng J Med 2000; 343: 254

          Information

          Journal history

          Keywords

          QR code

          Funding

          Support + Info: Here

           

           

          Directories and indexes

          Google Scholar profile

          Most read in the last 30 days

          Current Issue

          Sistema OJS 3.4.0.7 - Metabiblioteca |